ERBB2 and breast cancer: According to ESMO recommendations for BC molecular subtypes and their surrogate definitions, 36 cases (25.7%) were luminal A like, 27 (19.3%) were luminal B - HER2 negative like, 11 (7.9%) were luminal B - HER2-positive like, 22 (15,7%) were HER2 positive, and 44 (31,4%) were triple negative.